Due to recent acute coronary syndromes, patients with type 2 diabetes and high cardiovascular risk had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo. This is according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress."Compared with placebo, treatment with alogliptin resulted in ...
Read More
No comments:
Post a Comment